Positive Top-Line Phase 3 Results for Novel Myasthenia Gravis Drug
The novel self-administered subcutaneous peptide inhibitor zilucoplan met the primary and all secondary endpoints in a phase 3 study of adults with generalized myasthenia gravis. Medscape Medical News